Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2023-04-14 00:00:00 ET · period of report 2023-04-12 · accession 0001209191-23-024312 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-04-14 | 2023-04-12 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $326.70 | -7,567 | 42.3K | -15% | -$2.47M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-04-12 | S | D | 2,625 | $327.43 | 39,713 | D | — | — | (F2) Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F5) Open market sales reported on this line occurred at a weighted average price of $327.43 (range $327.01 to $327.91). |
| 2 | Common | Common Stock | 2023-04-12 | S | D | 874 | $325.70 | 46,406 | D | — | — | (F2) Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F3) Open market sales reported on this line occurred at a weighted average price of $325.70 (range $325.00 to $325.98). |
| 3 | Common | Common Stock | 2023-04-12 | S | D | 4,068 | $326.45 | 42,338 | D | — | — | (F2) Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F4) Open market sales reported on this line occurred at a weighted average price of $326.45 (range $326.00 to $326.99). |